CA2116465A1 - Conjugues polynucleotidiques antiviraux - Google Patents

Conjugues polynucleotidiques antiviraux

Info

Publication number: CA2116465A1
Authority: CA; Canada
Prior art keywords: polynucleotide; conjugate; polynucleotide conjugate; linker; strands
Prior art date: 1993-03-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2116465

Other languages

English (en)

Inventor

Shane Climie

Michael Y.-X. Ma

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allelix Biopharmaceuticals Inc

Original Assignee

Allelix Biopharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-01

Filing date

1994-02-25

Publication date

1994-09-02

1993-03-01 Priority claimed from US08/024,254 external-priority patent/US5495006A/en

1994-02-25 Application filed by Allelix Biopharmaceuticals Inc filed Critical Allelix Biopharmaceuticals Inc

1994-09-02 Publication of CA2116465A1 publication Critical patent/CA2116465A1/fr

Status Abandoned legal-status Critical Current

Links

108091033319 polynucleotide Proteins 0.000 title claims abstract description 170
102000040430 polynucleotide Human genes 0.000 title claims abstract description 170
239000002157 polynucleotide Substances 0.000 title claims abstract description 170
230000000840 anti-viral effect Effects 0.000 title description 5
230000027455 binding Effects 0.000 claims abstract description 68
108090000623 proteins and genes Proteins 0.000 claims abstract description 48
239000000126 substance Substances 0.000 claims abstract description 47
102000004169 proteins and genes Human genes 0.000 claims abstract description 34
239000003446 ligand Substances 0.000 claims abstract description 31
238000000034 method Methods 0.000 claims description 27
239000000203 mixture Substances 0.000 claims description 25
101150027427 ICP4 gene Proteins 0.000 claims description 18
125000004432 carbon atom Chemical group C* 0.000 claims description 13
238000000137 annealing Methods 0.000 claims description 12
241000700584 Simplexvirus Species 0.000 claims description 10
239000000523 sample Substances 0.000 claims description 10
238000012360 testing method Methods 0.000 claims description 9
230000000295 complement effect Effects 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
150000001335 aliphatic alkanes Chemical class 0.000 claims description 5
239000012472 biological sample Substances 0.000 claims description 5
239000005547 deoxyribonucleotide Substances 0.000 claims description 5
101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 claims description 4
125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
230000006648 viral gene expression Effects 0.000 claims description 4
208000009889 Herpes Simplex Diseases 0.000 claims description 3
230000010261 cell growth Effects 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 2
230000003602 anti-herpes Effects 0.000 claims 2
241000175212 Herpesvirales Species 0.000 claims 1
230000035899 viability Effects 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 8
108010052104 Viral Regulatory and Accessory Proteins Proteins 0.000 abstract description 2
208000036142 Viral infection Diseases 0.000 abstract description 2
230000000087 stabilizing effect Effects 0.000 abstract description 2
230000009385 viral infection Effects 0.000 abstract description 2
230000000415 inactivating effect Effects 0.000 abstract 1
230000029812 viral genome replication Effects 0.000 abstract 1
125000005647 linker group Chemical group 0.000 description 94
239000002773 nucleotide Substances 0.000 description 34
125000003729 nucleotide group Chemical group 0.000 description 33
101710149951 Protein Tat Proteins 0.000 description 30
125000004122 cyclic group Chemical group 0.000 description 30
210000004027 cell Anatomy 0.000 description 28
230000015572 biosynthetic process Effects 0.000 description 25
150000007523 nucleic acids Chemical class 0.000 description 23
238000003786 synthesis reaction Methods 0.000 description 23
238000010168 coupling process Methods 0.000 description 22
238000005859 coupling reaction Methods 0.000 description 22
230000008878 coupling Effects 0.000 description 21
108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
102000039446 nucleic acids Human genes 0.000 description 18
108020004707 nucleic acids Proteins 0.000 description 18
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
108091034117 Oligonucleotide Proteins 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
239000000499 gel Substances 0.000 description 14
238000011282 treatment Methods 0.000 description 14
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
239000000047 product Substances 0.000 description 13
239000000243 solution Substances 0.000 description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
-1 nucleotide deoxyribose sugars Chemical class 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
238000013459 approach Methods 0.000 description 9
239000000284 extract Substances 0.000 description 9
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
230000003622 anti-hsv Effects 0.000 description 8
238000003556 assay Methods 0.000 description 8
230000002255 enzymatic effect Effects 0.000 description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
238000010348 incorporation Methods 0.000 description 8
150000008300 phosphoramidites Chemical class 0.000 description 8
JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
241000700605 Viruses Species 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
238000010511 deprotection reaction Methods 0.000 description 7
238000011534 incubation Methods 0.000 description 7
230000003993 interaction Effects 0.000 description 7
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
239000003208 petroleum Substances 0.000 description 7
229920002401 polyacrylamide Polymers 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
238000004809 thin layer chromatography Methods 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
235000019439 ethyl acetate Nutrition 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000000159 protein binding assay Methods 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
229960001866 silicon dioxide Drugs 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
229910021529 ammonia Inorganic materials 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000001588 bifunctional effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
108091006104 gene-regulatory proteins Proteins 0.000 description 4
102000034356 gene-regulatory proteins Human genes 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000037230 mobility Effects 0.000 description 4
150000004712 monophosphates Chemical class 0.000 description 4
230000010076 replication Effects 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
238000005160 1H NMR spectroscopy Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
108010086093 Mung Bean Nuclease Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
101710086015 RNA ligase Proteins 0.000 description 3
108091028664 Ribonucleotide Proteins 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000005289 controlled pore glass Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000002336 ribonucleotide Substances 0.000 description 3
125000002652 ribonucleotide group Chemical group 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000002194 synthesizing effect Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
SFYDWLYPIXHPML-UHFFFAOYSA-N 3-nitro-1-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)N1N=C([N+]([O-])=O)N=C1 SFYDWLYPIXHPML-UHFFFAOYSA-N 0.000 description 2
125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101710125089 Bindin Proteins 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
108060002716 Exonuclease Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
230000006819 RNA synthesis Effects 0.000 description 2
108010081734 Ribonucleoproteins Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000008827 biological function Effects 0.000 description 2
244000309466 calf Species 0.000 description 2
239000013553 cell monolayer Substances 0.000 description 2
230000004700 cellular uptake Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
239000000470 constituent Substances 0.000 description 2
239000013068 control sample Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
230000030609 dephosphorylation Effects 0.000 description 2
238000006209 dephosphorylation reaction Methods 0.000 description 2
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
230000029087 digestion Effects 0.000 description 2
HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
150000002009 diols Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
102000013165 exonuclease Human genes 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
238000005304 joining Methods 0.000 description 2
101710130522 mRNA export factor Proteins 0.000 description 2
238000013507 mapping Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
238000002962 plaque-reduction assay Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
210000003501 vero cell Anatomy 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
QWTBDIBOOIAZEF-UHFFFAOYSA-N 3-[chloro-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile Chemical compound CC(C)N(C(C)C)P(Cl)OCCC#N QWTBDIBOOIAZEF-UHFFFAOYSA-N 0.000 description 1
238000004679 31P NMR spectroscopy Methods 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
101100240606 Caenorhabditis elegans scc-2 gene Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
108091023046 Deoxyribonucleoprotein Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
101150090364 ICP0 gene Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108700002232 Immediate-Early Genes Proteins 0.000 description 1
108010007403 Immediate-Early Proteins Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
QTUVCTXXMOZFHS-UHFFFAOYSA-N N-(8-aminooctyl)-2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetamide Chemical compound NCCCCCCCCNC(=O)COC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O QTUVCTXXMOZFHS-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102100034574 P protein Human genes 0.000 description 1
101710181008 P protein Proteins 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
101710177166 Phosphoprotein Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
238000003559 RNA-seq method Methods 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000008051 TBE buffer Substances 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
240000004922 Vigna radiata Species 0.000 description 1
235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Chemical class OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Chemical class OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000003235 crystal violet staining Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000006292 cyclic linker group Chemical group 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000006642 detritylation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229960005215 dichloroacetic acid Drugs 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
230000012447 hatching Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
SLPWXZZHNSOZPX-UHFFFAOYSA-N imidazole-1-carbonitrile Chemical compound N#CN1C=CN=C1 SLPWXZZHNSOZPX-UHFFFAOYSA-N 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
STEPQTYSZVCJPV-UHFFFAOYSA-N metazachlor Chemical compound CC1=CC=CC(C)=C1N(C(=O)CCl)CN1N=CC=C1 STEPQTYSZVCJPV-UHFFFAOYSA-N 0.000 description 1
CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000030147 nuclear export Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000005731 phosphitylation reaction Methods 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000166 polytrimethylene carbonate Polymers 0.000 description 1
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000010791 quenching Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
125000000548 ribosyl group Chemical class C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
244000000009 viral human pathogen Species 0.000 description 1
230000007484 viral process Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1
239000011686 zinc sulphate Substances 0.000 description 1
235000009529 zinc sulphate Nutrition 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

CA 2116465 1993-03-01 1994-02-25 Conjugues polynucleotidiques antiviraux Abandoned CA2116465A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/024,254		1993-03-01
US08/024,254 US5495006A (en)	1991-09-27	1993-03-01	Antiviral polynucleotide conjugates

Publications (1)

Publication Number	Publication Date
CA2116465A1 true CA2116465A1 (fr)	1994-09-02

Family

ID=21819648

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2116465 Abandoned CA2116465A1 (fr)	1993-03-01	1994-02-25	Conjugues polynucleotidiques antiviraux

Country Status (1)

Country	Link
CA (1)	CA2116465A1 (fr)

1994
- 1994-02-25 CA CA 2116465 patent/CA2116465A1/fr not_active Abandoned

Publication	Publication Date	Title
US5495006A (en)	1996-02-27	Antiviral polynucleotide conjugates
US6271358B1 (en)	2001-08-07	RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
KR100434213B1 (ko)	2004-09-10	포스포노모노에스테르핵산,이의제조방법및이를포함하는약제학적조성물
ORTIGÃO et al.	1992	Antisense effect of oligodeoxynucleotides with inverted terminal internucleotidic linkages: a minimal modification protecting against nucleolytic degradation
AU750469B2 (en)	2002-07-18	2'-O-aminoethyloxyethyl-modified oligonucleotides
EP2370451B1 (fr)	2016-11-16	Procédé pour la synthèse d'acides nucléiques modifiés au niveau de l'atome de phosphore
ES2244957T3 (es)	2005-12-16	Oligonucleotidos modificados, su preparacion, asi como su empleo.
JP4620810B2 (ja)	2011-01-26	ポリアミド−オリゴヌクレオチド誘導体、その製造及び使用
HU227794B1 (en)	2012-03-28	Oligonucleotide analogs compositions comprising same and process for producing them
IL185569A (en)	2012-02-29	Cyclic acid and analogues of nucleotide nucleotides and oligonucleotides
FI115400B (fi)	2005-04-29	Menetelmä oligoribonukleotidi- ja ribotsyymianalogien valmistamiseksi, joissa on terminaaliset 3 '-3'- tai 5'-5'-sidokset
JPH08512039A (ja)	1996-12-17	メチルホスホン酸エステル、その製造方法およびその使用
ES2275677T3 (es)	2007-06-16	Derivados de acido poliamidonucleico, agentes y procedimiento para su preparacion.
JP3676388B2 (ja)	2005-07-27	非ヌクレオチド基を有する３′−誘導されたオリゴヌクレオチド類似体、その製法および使用
Zon	1993	Oligonucleoside phosphorothioates
ES2335741T3 (es)	2010-04-05	Conjugados y procedimiento para su preparacion, asi como su uso para el transporte de moleculas a traves de membranas biologicas.
US6033909A (en)	2000-03-07	Oligonucleotide analogs, their preparation and use
KR100815067B1 (ko)	2008-03-20	음전하를 갖는 펩타이드 핵산 유도체, 이를 제조하기 위한제제 및 방법
WO1993006122A1 (fr)	1993-04-01	Conjugues polynucleotidiques a formation de doubles helices
Pandolfi et al.	1999	Evaluation of different types of end-capping modifications on the stability of oligonucleotides toward 3′-and 5′-exonucleases
CA2116465A1 (fr)	1994-09-02	Conjugues polynucleotidiques antiviraux
JPH11506107A (ja)	1999-06-02	求核試薬および一酸化炭素を用いるパラジウム触媒ヌクレオシド修飾方法
EP0558749A1 (fr)	1993-09-08	Derives d'acide nucleique non codant
Matulic-Adamic et al.	1995	Synthesis and incorporation of 2′-amino acid conjugated nucleotides into ribozymes
CA2129565A1 (fr)	1995-02-07	Composes oligonucleotides, leur production et leur utilisation

Legal Events

Date	Code	Title	Description
1999-02-25	FZDE	Dead